Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Format: | Article |
---|---|
Language: | English |
Published: |
BMJ Publishing Group
|
Series: | Stroke and Vascular Neurology |
Online Access: | https://svn.bmj.com/content/early/2022/09/28/svn-2022-001816corr1.full |
Similar Items
-
Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
by: Joanna M Wardlaw, et al. -
Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial
by: Jason P. Appleton, et al.
Published: (2019-07-01) -
Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial
by: Gordon W. Blair, et al.
Published: (2019-05-01) -
Isosorbide Mononitrate versus Misoprostol for Cervical Ripening
by: Abdul Razaq 0
Published: (2012-06-01) -
Isosorbide mononitrate promotes angiogenesis in embryonic development of zebrafish
by: Hui Lv, et al.
Published: (2020-07-01)